TY - JOUR
T1 - Recurrence of morphea after successful ultraviolet A1 phototherapy
T2 - A cohort study
AU - Vasquez, Rebecca
AU - Jabbar, Aysha
AU - Khan, Fatima
AU - Buethe, Douglas
AU - Ahn, Chul
AU - Jacobe, Heidi
N1 - Funding Information:
Research for this article was supported in part by National Institutes of Health (NIH) grant K23AR056303-4 . This work was conducted with support from UT-STAR, NIH/National Center for Advancing Translational Sciences (NCATS) grant UL1TR0000451 . The content is solely the responsibility of the authors and does not necessarily represent the official views of UT-STAR, University of Texas Southwestern Medical Center at Dallas and its affiliated academic and health care centers, NCATS, or NIH.
PY - 2014/3
Y1 - 2014/3
N2 - Background Studies support efficacy of ultraviolet (UV)A1 phototherapy, but little is known about recurrence after successful UVA1 treatment. Objective We sought to determine the frequency of recurrent activity after UVA1 phototherapy and variables associated with recurrence. Methods This was a case series and prospective cohort study of patients treated with UVA1 phototherapy with minimum 6 months of follow-up. Demographics, clinical features, and cumulative UVA1 dose were analyzed for association with recurrence. Results Of 37 patients, 46% (n = 17) had recurrence of active morphea lesions after successful UVA1 phototherapy. Two-year and 3-year (after the last UVA1 phototherapy treatment) recurrence rates were 44.5% (95% confidence interval 30.1%-62.2%) and 48.4% (95% confidence interval 33.2%-66.1%), respectively. The only variable associated with recurrence was duration of morphea before UVA1 (P value =.02, hazard ratio 1.15, 95% confidence interval 1.06-1.27). Limitations The sample size limits conclusions. Conclusion With the exception of increased duration of morphea, risk of recurrence is no different in adults and children, or between morphea subtypes, skin types, and medium- to high-dose regimens. This indicates treatment doses in the medium-high UVA1 range are adequate with respect to frequency of recurrence.
AB - Background Studies support efficacy of ultraviolet (UV)A1 phototherapy, but little is known about recurrence after successful UVA1 treatment. Objective We sought to determine the frequency of recurrent activity after UVA1 phototherapy and variables associated with recurrence. Methods This was a case series and prospective cohort study of patients treated with UVA1 phototherapy with minimum 6 months of follow-up. Demographics, clinical features, and cumulative UVA1 dose were analyzed for association with recurrence. Results Of 37 patients, 46% (n = 17) had recurrence of active morphea lesions after successful UVA1 phototherapy. Two-year and 3-year (after the last UVA1 phototherapy treatment) recurrence rates were 44.5% (95% confidence interval 30.1%-62.2%) and 48.4% (95% confidence interval 33.2%-66.1%), respectively. The only variable associated with recurrence was duration of morphea before UVA1 (P value =.02, hazard ratio 1.15, 95% confidence interval 1.06-1.27). Limitations The sample size limits conclusions. Conclusion With the exception of increased duration of morphea, risk of recurrence is no different in adults and children, or between morphea subtypes, skin types, and medium- to high-dose regimens. This indicates treatment doses in the medium-high UVA1 range are adequate with respect to frequency of recurrence.
KW - localized scleroderma
KW - morphea
KW - phototherapy
KW - ultraviolet A1 phototherapy
UR - http://www.scopus.com/inward/record.url?scp=84894046369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894046369&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2013.10.018
DO - 10.1016/j.jaad.2013.10.018
M3 - Article
C2 - 24365168
AN - SCOPUS:84894046369
SN - 0190-9622
VL - 70
SP - 481
EP - 488
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 3
ER -